Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2013. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding increases in their ordinary shareholdings.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to a specific share transaction price of 1382.27 pence per share on January 7, 2013.
Material Changes
The filing details increases in personal shareholdings for ten executives following the re-investment of dividends paid on January 3, 2013. There is no information regarding material changes to the company's financial position or operations compared to prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is strictly a regulatory disclosure of director share transactions in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Directors and senior managers increased their shareholdings on January 7, 2013, via dividend re-investment.
- The transaction price was 1382.27 pence per share.
- Notable increases included Mr. S A Hussain (832.047 shares) and Mr. M Dunoyer (370.787 shares).
- The company was advised of these transactions on January 9, 2013.